Cargando…
Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
BACKGROUND: Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depressio...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520499/ https://www.ncbi.nlm.nih.gov/pubmed/34657181 http://dx.doi.org/10.1007/s00520-021-06619-6 |
_version_ | 1784584685175701504 |
---|---|
author | Gokce Ceylan, Gamze Gok Metin, Zehra |
author_facet | Gokce Ceylan, Gamze Gok Metin, Zehra |
author_sort | Gokce Ceylan, Gamze |
collection | PubMed |
description | BACKGROUND: Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depression in BC patients receiving during paclitaxel regimen. MATERIALS AND METHODS: This descriptive and prospective study was conducted with 84 BC patients receiving paclitaxel regimen. “Chemotherapy Symptom Assessment Scale (C-SAS),” “Body Perception Scale (BPS),” and “Hospital Anxiety and Depression Scale (HADS)” were applied at five time points (T(1), before the first Paclitaxel infusion; T(2), at the end of first cycle; T(3), at the end of fourth cycle; T(4), at the end of eighth cycle; T(5), at the end of twelfth cycle). Data was analyzed using descriptive statistics, Cochrane Q, and linear mix model regression analysis. RESULTS: The frequency of needling and numbness in hands and feet, pain, and skin or nail changes significantly increased in the subsequent assessment points (T(2), T(3), T(4), and T(5)) compared to the initial assessment (T(1)) (p < 0.05). The mean scores of BPS significantly decreased at T(2), T(4), and T(5) compared to T(1) (F = 8.152, p < 0.001). The mean scores of the anxiety subscale of the HADS scale decreased at the T(3), T(4), and T(5) compared to T(1) (F = 6.865, p < 0.001), and the mean scores of the depression subscale significantly increased at the T(5) compared to T(1) (F = 3.708, p = 0.006). CONCLUSIONS: The oncology nurse should comprehensively evaluate the patients who scheduled to receive paclitaxel treatment, and provide counseling to the patients during these specific weeks. Better management of the symptoms that increase with the paclitaxel regimen with repeated interviews under the supervision of the nurse will also prevent the deterioration of body perception. In addition, since the risk of depression increases over time in patients receiving paclitaxel, nurses should periodically screen the risk of depression, and timely consult the patients for the appropriate support. |
format | Online Article Text |
id | pubmed-8520499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85204992021-10-18 Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study Gokce Ceylan, Gamze Gok Metin, Zehra Support Care Cancer Original Article BACKGROUND: Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depression in BC patients receiving during paclitaxel regimen. MATERIALS AND METHODS: This descriptive and prospective study was conducted with 84 BC patients receiving paclitaxel regimen. “Chemotherapy Symptom Assessment Scale (C-SAS),” “Body Perception Scale (BPS),” and “Hospital Anxiety and Depression Scale (HADS)” were applied at five time points (T(1), before the first Paclitaxel infusion; T(2), at the end of first cycle; T(3), at the end of fourth cycle; T(4), at the end of eighth cycle; T(5), at the end of twelfth cycle). Data was analyzed using descriptive statistics, Cochrane Q, and linear mix model regression analysis. RESULTS: The frequency of needling and numbness in hands and feet, pain, and skin or nail changes significantly increased in the subsequent assessment points (T(2), T(3), T(4), and T(5)) compared to the initial assessment (T(1)) (p < 0.05). The mean scores of BPS significantly decreased at T(2), T(4), and T(5) compared to T(1) (F = 8.152, p < 0.001). The mean scores of the anxiety subscale of the HADS scale decreased at the T(3), T(4), and T(5) compared to T(1) (F = 6.865, p < 0.001), and the mean scores of the depression subscale significantly increased at the T(5) compared to T(1) (F = 3.708, p = 0.006). CONCLUSIONS: The oncology nurse should comprehensively evaluate the patients who scheduled to receive paclitaxel treatment, and provide counseling to the patients during these specific weeks. Better management of the symptoms that increase with the paclitaxel regimen with repeated interviews under the supervision of the nurse will also prevent the deterioration of body perception. In addition, since the risk of depression increases over time in patients receiving paclitaxel, nurses should periodically screen the risk of depression, and timely consult the patients for the appropriate support. Springer Berlin Heidelberg 2021-10-17 2022 /pmc/articles/PMC8520499/ /pubmed/34657181 http://dx.doi.org/10.1007/s00520-021-06619-6 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Gokce Ceylan, Gamze Gok Metin, Zehra Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
title | Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
title_full | Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
title_fullStr | Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
title_full_unstemmed | Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
title_short | Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
title_sort | symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520499/ https://www.ncbi.nlm.nih.gov/pubmed/34657181 http://dx.doi.org/10.1007/s00520-021-06619-6 |
work_keys_str_mv | AT gokceceylangamze symptomstatusbodyperceptionandriskofanxietyanddepressioninbreastcancerpatientsreceivingpaclitaxelaprospectivelongitudinalstudy AT gokmetinzehra symptomstatusbodyperceptionandriskofanxietyanddepressioninbreastcancerpatientsreceivingpaclitaxelaprospectivelongitudinalstudy |